Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.41 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.41 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272638 | 1.00 | SIGMAR1 (0.51) | SIGMAR1POLBHSD17B10HTTL3MBTL3 | |
| SCHEMBL3272642 | 1.00 | SIGMAR1 (0.51) | SIGMAR1POLBHSD17B10HTTL3MBTL3 | |
| SCHEMBL4777482 | 0.98 | SIGMAR1 (0.54) | SIGMAR1POLBHSD17B10HTTL3MBTL3 | |
| SCHEMBL4777474 | 0.98 | SIGMAR1 (0.54) | SIGMAR1POLBHSD17B10HTTL3MBTL3 | |
| Oxalic Acid SCHEMBL4158692 | 0.96 | SIGMAR1 (0.49) | SIGMAR1POLBHSD17B10HTTL3MBTL3 | |
| SCHEMBL22191535 | 0.96 | SIGMAR1 (0.48) | SIGMAR1POLBHSD17B10HTTL3MBTL3 | |
| SCHEMBL22208127 | 0.88 | POLB (0.46) | SIGMAR1POLBHSD17B10HTTMEN1 | |
| SCHEMBL23573288 | 0.84 | POLB (0.56) | SIGMAR1POLBHSD17B10HTTCHRM5 | |
| SCHEMBL3369574 | 0.84 | POLB (0.51) | SIGMAR1POLBHSD17B10CHRM5CHRM1 | |
| SCHEMBL854180 | 0.83 | PDE7A (0.46) | SIGMAR1POLBHSD17B10L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2597955-B1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-9120749-B2 | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NADK, NEK1 | SIGMAR1 3141/4885POLB 2238/4885HSD17B10 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.